Keudell Kymera Therapeutics, Inc. Transaction History
Keudell
- $422 Million
- Q2 2025
A detailed history of Keudell transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Keudell holds 7,660 shares of KYMR stock, worth $305,404. This represents 0.08% of its overall portfolio holdings.
Number of Shares
7,660Holding current value
$305,404% of portfolio
0.08%Shares
4 transactions
Others Institutions Holding KYMR
# of Institutions
191Shares Held
69.7MCall Options Held
223KPut Options Held
241K-
Price T Rowe Associates Inc Baltimore, MD6.7MShares$267 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.46MShares$258 Million2.86% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$239 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$239 Million1.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$224 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.18B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...